CoChat

Tumor Microenvironment-Responsive Nanomedicine: Monitoring and Modulating the Tumor Microenvironment for Precision Cancer Therapy

Open access
He, Jiejie, Xue, Weiwei, Li, Yan · 2026 · International Journal of Nanomedicine

The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.

Abstract

The tumor microenvironment (TME) is a dynamic and heterogeneous ecosystem whose abnormal vasculature, dense extracellular matrix, metabolic reprogramming and immunosuppression collectively hinder drug penetration, drive therapeutic resistance and limit responses to immunotherapy. TME-responsive nanomedicine provides an emerging toolbox to both monitor and actively remodel the microenvironment for precision cancer therapy. In this narrative review, we first summarize key pathological features of the TME and their impact on drug delivery across classical barriers, including the blood-brain, cutaneous and ocular interfaces, as well as circulating and bone-marrow niches in hematologic malignancies. We then discuss design principles of endogenous and exogenous stimuli-responsive nanoplatforms, and how these systems enable TME monitoring via liquid biopsy, spatial multi-omics and real-time imaging, and TME modulation through metabolic reprogramming, immune activation, vascular normalization and extracellular-matrix remodeling. Finally, we highlight major translational challenges and future opportunities, emphasizing the roles of artificial intelligence, multiscale and quantum-inspired modeling, and closed-loop theranostic strategies in optimizing TME-responsive nanomedicines for clinically meaningful benefit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ijn.s560983

Cites

191 of 191 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY-NC · PubMed Central
Figure 1 Multiscale interactions between cancer cells and the tumor microenvironment (TME). Intrinsic genomic alterations, epigenetic dysregulation and accumulation of mutations drive malignant transformation of cancer cells, leading to metabolic reprogramming and immune evasion. Externally, a dense and stiff extracellular matrix (ECM) rich in collagen and fibronectin, together with cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), regulatory T cells (Tregs) and abnormal blood vessels, creates a mechanically and biochemically hostile milieu characterized by lactic acid accumulation and immunosuppressive cytokines such as IL-10 and TGF-β. These cellular and non-cellular components cooperatively promote epithelial-mesenchymal transition (EMT), tumor invasion and metastasis, while establishing physical and immunological barriers that hinder drug penetration and anti-tumor immunity.
Figure 1 Multiscale interactions between cancer cells and the tumor microenvironment (TME). Intrinsic genomic alterations, epigenetic dysregulation and accumulation of mutations drive malignant transformation of cancer cells, leading to metabolic reprogramming and immune evasion. Externally, a dense and stiff extracellular matrix (ECM) rich in collagen and fibronectin, together with cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), regulatory T cells (Tregs) and abnormal blood vessels, creates a mechanically and biochemically hostile milieu characterized by lactic acid accumulation and immunosuppressive cytokines such as IL-10 and TGF-β. These cellular and non-cellular components cooperatively promote epithelial-mesenchymal transition (EMT), tumor invasion and metastasis, while establishing physical and immunological barriers that hinder drug penetration and anti-tumor immunity.CC BY-NC · PubMed Central
Figure 2 Pathophysiological determinants of nanoparticle delivery in solid tumors and hierarchical targeting strategies. Schematic comparison of healthy tissue (left) and tumor tissue (right) showing how continuous vascular endothelium and efficient lymphatic drainage in normal tissues restrict nanoparticle extravasation and retention, whereas defective angiogenic vessels, impaired lymphatic drainage, and a dense tumor microenvironment (TME) composed of cancer cells, diverse immune cells and cancer-associated fibroblasts (CAFs) embedded in extracellular matrix components (proteoglycans, hyaluronic acid, collagen and laminin) generate heterogeneous permeability and interstitial pressure. These features underlie the enhanced permeability and retention (EPR) effect but also create multiscale transport barriers. The lower panels illustrate the hierarchical design of nanomedicine from passive targeting (size/shape/charge-dependent accumulation at tumor sites), through active targeting (ligand-mediated or stimuli-responsive enrichment in tumor regions), to cellular targeting (selective uptake by specific cancer, stromal or immune cell subsets), which together enable better matching between nanoparticle properties and complex TMEs discussed in this review.
Figure 2 Pathophysiological determinants of nanoparticle delivery in solid tumors and hierarchical targeting strategies. Schematic comparison of healthy tissue (left) and tumor tissue (right) showing how continuous vascular endothelium and efficient lymphatic drainage in normal tissues restrict nanoparticle extravasation and retention, whereas defective angiogenic vessels, impaired lymphatic drainage, and a dense tumor microenvironment (TME) composed of cancer cells, diverse immune cells and cancer-associated fibroblasts (CAFs) embedded in extracellular matrix components (proteoglycans, hyaluronic acid, collagen and laminin) generate heterogeneous permeability and interstitial pressure. These features underlie the enhanced permeability and retention (EPR) effect but also create multiscale transport barriers. The lower panels illustrate the hierarchical design of nanomedicine from passive targeting (size/shape/charge-dependent accumulation at tumor sites), through active targeting (ligand-mediated or stimuli-responsive enrichment in tumor regions), to cellular targeting (selective uptake by specific cancer, stromal or immune cell subsets), which together enable better matching between nanoparticle properties and complex TMEs discussed in this review.CC BY-NC · PubMed Central
Figure 3 Endogenous and exogenous stimuli-responsive nanocarriers enabling smart drug release across organ-specific tumor microenvironments. Representative nanocarrier platforms, including liposomes, lipid nanoparticles, polymeric micelles, gold nanoparticles, exosomes, magnetic nanocarriers, protein-based nanomaterials, hyaluronic acid (HA) nanocarriers, RNA nanocarriers and DNAzyme nanocarriers, are shown in the inner ring, together with exemplary applications in brain, skin and ocular cancers. The outer ring summarizes key endogenous cues in the tumor microenvironment (enzyme activity, hypoxia, reactive oxygen species (ROS), pH and metabolic reprogramming) and exogenous physical stimuli (light, heat, magnetic field, optothermal excitation and ultrasound) that can be harnessed to trigger spatiotemporally controlled drug release. The bottom sector highlights the concept of multi-responsive systems capable of integrating early-stage (circulation and accumulation) and late-stage (penetration, cellular uptake and intracellular trafficking) responses for precision nanotherapy, as elaborated in the sections on TME-adaptive design principles.
Figure 3 Endogenous and exogenous stimuli-responsive nanocarriers enabling smart drug release across organ-specific tumor microenvironments. Representative nanocarrier platforms, including liposomes, lipid nanoparticles, polymeric micelles, gold nanoparticles, exosomes, magnetic nanocarriers, protein-based nanomaterials, hyaluronic acid (HA) nanocarriers, RNA nanocarriers and DNAzyme nanocarriers, are shown in the inner ring, together with exemplary applications in brain, skin and ocular cancers. The outer ring summarizes key endogenous cues in the tumor microenvironment (enzyme activity, hypoxia, reactive oxygen species (ROS), pH and metabolic reprogramming) and exogenous physical stimuli (light, heat, magnetic field, optothermal excitation and ultrasound) that can be harnessed to trigger spatiotemporally controlled drug release. The bottom sector highlights the concept of multi-responsive systems capable of integrating early-stage (circulation and accumulation) and late-stage (penetration, cellular uptake and intracellular trafficking) responses for precision nanotherapy, as elaborated in the sections on TME-adaptive design principles.CC BY-NC · PubMed Central
Figure 4 Stimuli-responsive nanoplatforms for monitoring and mediating the tumor microenvironment (TME). Representative nanocarriers, including liposomes, lipid nanoparticles, gold nanoparticles, micelles, exosomes, magnetic nanocarriers, protein-based nanomaterials, hyaluronic acid (HA) nanocarriers, RNA nanocarriers and DNAzyme nanocarriers, can be engineered to respond to diverse endogenous stimuli (low pH, reactive oxygen species (ROS), oxygen deficit, metabolic cues and enzymes) and exogenous stimuli (light, heat, magnetism, optothermal triggers and ultrasound). These systems support multiparametric monitoring of the TME through liquid biopsy, spatial multi-omics, real-time imaging and dynamic longitudinal assessment, and can actively remodel the TME by modulating glycolysis and mitochondrial respiration, altering metabolic and biochemical markers, reprogramming the immune microenvironment, regulating the physical microenvironment and integrating advanced technological applications for precision therapy.
Figure 4 Stimuli-responsive nanoplatforms for monitoring and mediating the tumor microenvironment (TME). Representative nanocarriers, including liposomes, lipid nanoparticles, gold nanoparticles, micelles, exosomes, magnetic nanocarriers, protein-based nanomaterials, hyaluronic acid (HA) nanocarriers, RNA nanocarriers and DNAzyme nanocarriers, can be engineered to respond to diverse endogenous stimuli (low pH, reactive oxygen species (ROS), oxygen deficit, metabolic cues and enzymes) and exogenous stimuli (light, heat, magnetism, optothermal triggers and ultrasound). These systems support multiparametric monitoring of the TME through liquid biopsy, spatial multi-omics, real-time imaging and dynamic longitudinal assessment, and can actively remodel the TME by modulating glycolysis and mitochondrial respiration, altering metabolic and biochemical markers, reprogramming the immune microenvironment, regulating the physical microenvironment and integrating advanced technological applications for precision therapy.CC BY-NC · PubMed Central
Figure 5 TME-responsive nanomedicines remodeling “cold” tumors into “hot” tumors and synergizing with immunotherapy. Left: immunologically “cold” tumors are characterized by poor T-cell infiltration, abundant fibroblasts and regulatory immune cells, and an immunosuppressive milieu. Various TME-modulating nanomedicines, such as zinc-releasing formulations (Zn2⁺ nanocomposites), CAT@CaCO3 nanoparticles and other immunogenic nanoplatforms, are used to induce immunogenic cell death (ICD), reprogram tumor-associated macrophages from the M2 to the M1 phenotype, and activate DNA-driven innate immune pathways (cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling) and Toll-like receptor 7/8 (TLR7/8). The central panel illustrates how these effects increase type I interferon (IFN) and inflammatory cytokines (eg, IL-6, TNF), enhance antigen presentation, and potentiate immune-checkpoint blockade (anti-PD-1/PD-L1 and anti-CTLA-4 antibodies) delivered by nanovaccines, liposomes and other carriers. Right: the remodeled “hot” tumor displays dense infiltration of effector CD8⁺ T cells and natural killer (NK) cells with strengthened antitumor immunity, consistent with the review’s discussion of TME-responsive nanomedicine as a bridge between metabolic/innate immune modulation and adaptive immunotherapy.
Figure 5 TME-responsive nanomedicines remodeling “cold” tumors into “hot” tumors and synergizing with immunotherapy. Left: immunologically “cold” tumors are characterized by poor T-cell infiltration, abundant fibroblasts and regulatory immune cells, and an immunosuppressive milieu. Various TME-modulating nanomedicines, such as zinc-releasing formulations (Zn2⁺ nanocomposites), CAT@CaCO3 nanoparticles and other immunogenic nanoplatforms, are used to induce immunogenic cell death (ICD), reprogram tumor-associated macrophages from the M2 to the M1 phenotype, and activate DNA-driven innate immune pathways (cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling) and Toll-like receptor 7/8 (TLR7/8). The central panel illustrates how these effects increase type I interferon (IFN) and inflammatory cytokines (eg, IL-6, TNF), enhance antigen presentation, and potentiate immune-checkpoint blockade (anti-PD-1/PD-L1 and anti-CTLA-4 antibodies) delivered by nanovaccines, liposomes and other carriers. Right: the remodeled “hot” tumor displays dense infiltration of effector CD8⁺ T cells and natural killer (NK) cells with strengthened antitumor immunity, consistent with the review’s discussion of TME-responsive nanomedicine as a bridge between metabolic/innate immune modulation and adaptive immunotherapy.CC BY-NC · PubMed Central
Figure 6 TME-oriented theranostic nanoplatforms enabling closed-loop, imaging-guided precision therapy and drug-resistance overcoming. Schematic illustration of a solid tumor with aberrant vasculature and dense extracellular matrix (ECM) within the tumor microenvironment (TME), surrounded by multifunctional nanoplatforms. Stimuli-responsive nanoparticles (left) undergo structural changes and on-demand drug release in response to TME cues such as acidic pH, redox imbalance, and ROS, while some formulations simultaneously modulate ECM architecture to improve penetration. On the right, ligand-decorated carriers (eg, RGD, folate) achieve receptor-mediated targeting, and combinatorial nanosystems co-regulate metabolic-immune pathways including the lactate-adenosine axis, PD-1/PD-L1 and cGAS-STING, thereby converting “cold” tumors into “hot” tumors and overcoming multidrug resistance. At the bottom, theranostic nanocarriers integrate CT/MR/PA/fluorescence contrast with therapeutic payloads to realize real-time tracking of intratumoral distribution and response. At the top, patient-side clinical treatment, multimodal imaging readouts, and in silico modeling (eg, Monte Carlo simulations) are linked by feedback arrows, highlighting a data-driven closed loop in which TME monitoring informs nanoplatform optimization and treatment adaptation for visualized precision cancer therapy.
Figure 6 TME-oriented theranostic nanoplatforms enabling closed-loop, imaging-guided precision therapy and drug-resistance overcoming. Schematic illustration of a solid tumor with aberrant vasculature and dense extracellular matrix (ECM) within the tumor microenvironment (TME), surrounded by multifunctional nanoplatforms. Stimuli-responsive nanoparticles (left) undergo structural changes and on-demand drug release in response to TME cues such as acidic pH, redox imbalance, and ROS, while some formulations simultaneously modulate ECM architecture to improve penetration. On the right, ligand-decorated carriers (eg, RGD, folate) achieve receptor-mediated targeting, and combinatorial nanosystems co-regulate metabolic-immune pathways including the lactate-adenosine axis, PD-1/PD-L1 and cGAS-STING, thereby converting “cold” tumors into “hot” tumors and overcoming multidrug resistance. At the bottom, theranostic nanocarriers integrate CT/MR/PA/fluorescence contrast with therapeutic payloads to realize real-time tracking of intratumoral distribution and response. At the top, patient-side clinical treatment, multimodal imaging readouts, and in silico modeling (eg, Monte Carlo simulations) are linked by feedback arrows, highlighting a data-driven closed loop in which TME monitoring informs nanoplatform optimization and treatment adaptation for visualized precision cancer therapy.CC BY-NC · PubMed Central
Figure 7 Convergence of artificial intelligence and nanotechnology for tumor microenvironment-oriented precision nanomedicine. Schematic illustration of AI-driven design and application of multifunctional nanoplatforms within a complex tumor microenvironment. At the centre, a solid tumor with abnormal vasculature and dense extracellular matrix is surrounded by diverse nanosystems, including lipid nanoparticles, gold-silver core-shell nanoparticles, gold nanoparticles, metal/metal-oxide nanozymes, tiny magnetically guided micro/nanorobots and spiral “spirulina-like” magnetic robots. Above the tumor, a central “AI brain” integrates information from a virtual material-design laboratory, Monte Carlo simulations, multiscale transport models and 3D bioprinted tumor chips, as well as high-dimensional maps of immune-cell infiltration and metabolism. On the right, high-sensitivity diagnostic platforms such as SERS chips, DNA-origami nanopore sensors and flexible crack-pattern wearable sensors provide multimodal molecular and physiological readouts. Together, these elements depict a closed-loop, data-driven framework in which AI-guided virtual screening, multimodal TME monitoring and intelligent nanocarriers jointly enable rational design and real-time optimization of TME-oriented precision therapy.
Figure 7 Convergence of artificial intelligence and nanotechnology for tumor microenvironment-oriented precision nanomedicine. Schematic illustration of AI-driven design and application of multifunctional nanoplatforms within a complex tumor microenvironment. At the centre, a solid tumor with abnormal vasculature and dense extracellular matrix is surrounded by diverse nanosystems, including lipid nanoparticles, gold-silver core-shell nanoparticles, gold nanoparticles, metal/metal-oxide nanozymes, tiny magnetically guided micro/nanorobots and spiral “spirulina-like” magnetic robots. Above the tumor, a central “AI brain” integrates information from a virtual material-design laboratory, Monte Carlo simulations, multiscale transport models and 3D bioprinted tumor chips, as well as high-dimensional maps of immune-cell infiltration and metabolism. On the right, high-sensitivity diagnostic platforms such as SERS chips, DNA-origami nanopore sensors and flexible crack-pattern wearable sensors provide multimodal molecular and physiological readouts. Together, these elements depict a closed-loop, data-driven framework in which AI-guided virtual screening, multimodal TME monitoring and intelligent nanocarriers jointly enable rational design and real-time optimization of TME-oriented precision therapy.CC BY-NC · PubMed Central
Figure 8 Biomimetic and living nanotechnology for enhanced tumor microenvironment-targeted delivery. Schematic comparison between conventional inorganic nanoparticles (left) and biomimetic/living nano-bio platforms (right) in crossing biological barriers and reaching deep tumor regions. In the left panel, simple inorganic nanoparticles extravasate from a blood vessel into a solid tumor but are rapidly cleared or trapped within the peripheral matrix, showing limited penetration into the hypoxic core and suboptimal interaction with immune cells. In the right panel, cell membrane-coated nanoparticles, natural exosomes and exosome-mimetic vesicles exhibit prolonged circulation, immune evasion and efficient translocation across the blood-brain barrier and mucosal barriers, enabling improved drug delivery. Living and semi-living carriers, including engineered CAR-T cells, macrophages and attenuated bacteria, actively home to tumor and hypoxic niches while transporting nanotherapeutics. Programmable artificial cells assembled from modular components sense local pH and enzyme activity and autonomously regulate drug release. Together, these biomimetic and living systems illustrate next-generation strategies to overcome spatiobiological barriers and achieve precise, TME-oriented cancer therapy.
Figure 8 Biomimetic and living nanotechnology for enhanced tumor microenvironment-targeted delivery. Schematic comparison between conventional inorganic nanoparticles (left) and biomimetic/living nano-bio platforms (right) in crossing biological barriers and reaching deep tumor regions. In the left panel, simple inorganic nanoparticles extravasate from a blood vessel into a solid tumor but are rapidly cleared or trapped within the peripheral matrix, showing limited penetration into the hypoxic core and suboptimal interaction with immune cells. In the right panel, cell membrane-coated nanoparticles, natural exosomes and exosome-mimetic vesicles exhibit prolonged circulation, immune evasion and efficient translocation across the blood-brain barrier and mucosal barriers, enabling improved drug delivery. Living and semi-living carriers, including engineered CAR-T cells, macrophages and attenuated bacteria, actively home to tumor and hypoxic niches while transporting nanotherapeutics. Programmable artificial cells assembled from modular components sense local pH and enzyme activity and autonomously regulate drug release. Together, these biomimetic and living systems illustrate next-generation strategies to overcome spatiobiological barriers and achieve precise, TME-oriented cancer therapy.CC BY-NC · PubMed Central
Figure 9 Systems-level challenges and opportunities for translating TME-oriented nanotechnology into clinical precision therapy. Schematic representation of the bench-to-bedside pathway for nanomedicines, highlighting key hurdles in blood compatibility, large-scale assembly and dynamic tumor microenvironment (TME) adaptation. On the left, candidate nanosystems are engineered and characterized in the laboratory, where surface chemistries such as PEGylation or biodegradable coatings determine interactions with complement and antibodies, thereby influencing circulation time and immune safety in blood. In the middle, manufacturing and quality-control steps aim to convert complex theranostic designs into composition-controlled, batch-consistent formulations, while AI models and multiscale simulations are iteratively refined using multimodal TME readouts (immune infiltration, ECM density, hypoxia, metabolic profiles). Over time, tumors evolve from initial lesions to fibrotic, hypoxic and immunosuppressive states, necessitating pre-planned “second-wave” interventions that counter adaptive resistance. On the right, non-invasive clinical modalities-including photodynamic therapy, sonodynamic therapy, radiosensitization and nano-immunotherapy are integrated with TME-responsive nanoplatforms and AI/data loops to enable treatment monitoring and adaptive optimization in real patients, emphasizing the need to balance functionality, structural simplicity and translational feasibility.
Figure 9 Systems-level challenges and opportunities for translating TME-oriented nanotechnology into clinical precision therapy. Schematic representation of the bench-to-bedside pathway for nanomedicines, highlighting key hurdles in blood compatibility, large-scale assembly and dynamic tumor microenvironment (TME) adaptation. On the left, candidate nanosystems are engineered and characterized in the laboratory, where surface chemistries such as PEGylation or biodegradable coatings determine interactions with complement and antibodies, thereby influencing circulation time and immune safety in blood. In the middle, manufacturing and quality-control steps aim to convert complex theranostic designs into composition-controlled, batch-consistent formulations, while AI models and multiscale simulations are iteratively refined using multimodal TME readouts (immune infiltration, ECM density, hypoxia, metabolic profiles). Over time, tumors evolve from initial lesions to fibrotic, hypoxic and immunosuppressive states, necessitating pre-planned “second-wave” interventions that counter adaptive resistance. On the right, non-invasive clinical modalities-including photodynamic therapy, sonodynamic therapy, radiosensitization and nano-immunotherapy are integrated with TME-responsive nanoplatforms and AI/data loops to enable treatment monitoring and adaptive optimization in real patients, emphasizing the need to balance functionality, structural simplicity and translational feasibility.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Netti, 2000, Cancer Res, 60, 2497
  2. Gabizon, 1994, Cancer Res, 54, 987

Cited by

See all 18

Metadata

Authors
He, J., Xue, W., & Li, Y.
Affiliations
Qinghai University (CN)
Corresponding author
Li, Yan
Venue
International Journal of Nanomedicine
Published
2026-03
Volume
Volume 21
Pages
1-38
ISSN
  • 1176-9114 (ISSN-L)
  • 1178-2013
OpenAlex
W7138845632
Cited by
16
References
189
Citations by year
2026: 16
FWCI
6.95
Type
journal article
Language
en
Open access
Locations
  • International Journal of Nanomedicine (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Keywords
tumor microenvironment, stimuli-responsive nanomedicine, precision cancer therapy, drug delivery barriers, blood-brain barrier, ocular drug delivery, bone marrow microenvironment, hematologic malignancies, liquid biopsy, spatial multi-omics, real-time imaging, metabolic reprogramming, immune activation, vascular normalization, extracellular matrix remodeling, immunosuppression, treatment resistance, artificial intelligence in drug design, quantum-inspired modeling
MeSH terms
Theranostic Nanomedicine, Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, Nanomedicine, Nanoparticles, Precision Medicine, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.